Member, Oversight Committee
Michael Helmus has over 3 decades of experience leading and managing the R&D of medical and controlled drug delivery devices. He has a focus on developing commercialization strategies of potentially disruptive technology as well as managing intellectual property development (44 issued US patents). Dr. Helmus has experience with patent litigation. Michael has strong skills in assessing emergent technologies and products, incubating emergent technologies and identifying “White Space” opportunities and how they may impact future medical therapeutics, particularly in these times of change. His consulting casework over the past few years has been with technologies, established and emerging companies ranging from orthopedic, cardiovascular, less invasive devices, wound care, and opthalmic devices with a range of unique technologies ranging from nanoenabled, magnetic nano-particle drug delivery, bioactive, biocompatible and thromboresistant coatings, electrospun polymers, injectable polymers, therapeutic NO and statin releasing polymers, Point of Care Diagnostics and both drug and cellular combination devices. He has reviewed the emergence of nanoenabled sensors and the impact in the evolving field of personalized medicine.
He currently works as a consultant in medical devices, drug delivery, tissue engineering, and nanotechnology, as well as a Research Professor in the Department of Mechanical Engineering at Worcester Polytechnic Institute. He previously held Vice President and Director positions at Advance Nanotech, Boston Scientific, Edwards Lifesciences, Baxter, Pfizer, St. Jude Medical, and Bard.